Overcoming barriers to patient adherence: the case for developing innovative drug delivery systems
TH Baryakova, BH Pogostin, R Langer… - Nature Reviews Drug …, 2023 - nature.com
Poor medication adherence is a pervasive issue with considerable health and
socioeconomic consequences. Although the underlying reasons are generally understood …
socioeconomic consequences. Although the underlying reasons are generally understood …
Barriers to the wider use of pre-exposure prophylaxis in the United States: a narrative review
Antiretroviral pre-exposure prophylaxis (PrEP) to prevent HIV transmission was first
approved by the US Food and Drug Administration in 2012. Despite correlations of …
approved by the US Food and Drug Administration in 2012. Despite correlations of …
Cabotegravir for the prevention of HIV-1 in women: results from HPTN 084, a phase 3, randomised clinical trial
S Delany-Moretlwe, JP Hughes, P Bock, SG Ouma… - The Lancet, 2022 - thelancet.com
Background Oral pre-exposure prophylaxis has been introduced in more than 70 countries,
including many in sub-Saharan Africa, but women experience considerable barriers to daily …
including many in sub-Saharan Africa, but women experience considerable barriers to daily …
[HTML][HTML] Cabotegravir for HIV prevention in cisgender men and transgender women
RJ Landovitz, D Donnell, ME Clement… - … England Journal of …, 2021 - Mass Medical Soc
Background Safe and effective long-acting injectable agents for preexposure prophylaxis
(PrEP) for human immunodeficiency virus (HIV) infection are needed to increase the options …
(PrEP) for human immunodeficiency virus (HIV) infection are needed to increase the options …
Emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis (DISCOVER): primary results from a …
KH Mayer, JM Molina, MA Thompson, PL Anderson… - The Lancet, 2020 - thelancet.com
Background Tenofovir alafenamide shows high antiviral efficacy and improved renal and
bone safety compared with tenofovir disoproxil fumarate when used for HIV treatment. Here …
bone safety compared with tenofovir disoproxil fumarate when used for HIV treatment. Here …
Clinical targeting of HIV capsid protein with a long-acting small molecule
JO Link, MS Rhee, WC Tse, J Zheng, JR Somoza… - Nature, 2020 - nature.com
Oral antiretroviral agents provide life-saving treatments for millions of people living with HIV,
and can prevent new infections via pre-exposure prophylaxis,,,–. However, some people …
and can prevent new infections via pre-exposure prophylaxis,,,–. However, some people …
Association of HIV preexposure prophylaxis with incidence of sexually transmitted infections among individuals at high risk of HIV infection
Importance Emerging evidence suggests that risk of bacterial sexually transmitted infections
(STIs) increases among gay and bisexual men following initiation of HIV preexposure …
(STIs) increases among gay and bisexual men following initiation of HIV preexposure …
中国艾滋病防治面临新形势与新挑战
吴尊友 - 中国公共卫生, 2011 - cqvip.com
今年是世界艾滋病流行以来的第30 个年头, 全球艾滋病流行与防治形势都发生了巨大的变化.
自上世纪九十年代中期高效联合抗逆转录病毒治疗(highly active antiretroviral therapy …
自上世纪九十年代中期高效联合抗逆转录病毒治疗(highly active antiretroviral therapy …
Sexually transmitted infections: challenges ahead
WHO estimated that nearly 1 million people become infected every day with any of four
curable sexually transmitted infections (STIs): chlamydia, gonorrhoea, syphilis, and …
curable sexually transmitted infections (STIs): chlamydia, gonorrhoea, syphilis, and …
[HTML][HTML] HIV preexposure prophylaxis, by race and ethnicity—United States, 2014–2016
AH Ya-lin - MMWR. Morbidity and mortality weekly report, 2018 - cdc.gov
HIV Preexposure Prophylaxis, by Race and Ethnicity — United States, 2014–2016 | MMWR
Skip directly to site content Skip directly to page options Skip directly to AZ link Centers for …
Skip directly to site content Skip directly to page options Skip directly to AZ link Centers for …